Disease Markers

Disease Markers / 2013 / Article

Open Access

Volume 34 |Article ID 842130 | https://doi.org/10.3233/DMA-130990

Nuria Sánchez-Otero, Sonia Blanco-Prieto, Lorena Vázquez-Iglesias, María Páez de la Cadena, Alberto Fernández-Villar, María Isabel Botana-Rial, Francisco Javier Rodríguez-Berrocal, "Levels of PEDF in Pleural Effusions from Lung Adenocarcinoma and Benign Disease Patients", Disease Markers, vol. 34, Article ID 842130, 6 pages, 2013. https://doi.org/10.3233/DMA-130990

Levels of PEDF in Pleural Effusions from Lung Adenocarcinoma and Benign Disease Patients

Received12 Apr 2013
Accepted12 Apr 2013

Abstract

Anti-tumor properties assigned to PEDF, beside its role as an inhibitor of angiogenesis, make it a promising candidate in the search of new biomarkers for malignancy. In this study levels of PEDF were investigated in pleural effusions from lung adenocarcinoma and benign inflammatory disease patients. The mean PEDF concentration in the malignant group was slightly superior to that in patients suffering benign diseases (4.59 μg/mL vs 3.97 μg/mL), although the difference did not reach statistical significance (P 0.166). Pleural effusion PEDF levels were not related to gender, age, smoking habit or pleural effusion size. We also investigated the possible relationship of PEDF levels in pleural effusion regarding clinicopathological features. Correlations were found for monocytes (P 0.010) and polymorphonuclear leukocytes (P 0.023) with PEDF levels in pleural effusion of malignant origin.

Copyright © 2013 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views573
Downloads692
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.